These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26568592)

  • 1. Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study.
    Haugeberg G; Bøyesen P; Helgetveit K; Prøven A
    J Rheumatol; 2015 Dec; 42(12):2279-87. PubMed ID: 26568592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
    J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
    Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
    Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
    Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
    Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
    J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
    Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
    Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
    Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting.
    Sanmarti R; Gomez A; Ercilla G; Gratacos J; Larrosa M; Suris X; Vinas O; Salvador G; Munoz-Gomez J; Canete JD
    Rheumatology (Oxford); 2003 Sep; 42(9):1044-9. PubMed ID: 12730518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study.
    Hafström I; Albertsson K; Boonen A; van der Heijde D; Landewé R; Svensson B;
    Ann Rheum Dis; 2009 Apr; 68(4):508-13. PubMed ID: 18420939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.
    Quintana-Duque MA; Rondon-Herrera F; Mantilla RD; Calvo-Paramo E; Yunis JJ; Varela-Nariño A; Restrepo JF; Iglesias-Gamarra A
    Clin Rheumatol; 2016 Jun; 35(6):1463-73. PubMed ID: 27041382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
    Haugeberg G; Hansen IJ; Soldal DM; Sokka T
    Arthritis Res Ther; 2015 Aug; 17(1):219. PubMed ID: 26290061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of early radiographic remission on the 15-year radiographic outcome in patients with rheumatoid arthritis.
    Tiippana-Kinnunen T; Laasonen L; Kautiainen H; Paimela L; Leirisalo-Repo M
    Scand J Rheumatol; 2011; 40(4):263-8. PubMed ID: 21417549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
    Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
    Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
    Wassenberg S; Rau R; Steinfeld P; Zeidler H
    Arthritis Rheum; 2005 Nov; 52(11):3371-80. PubMed ID: 16255011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
    Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
    Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.